secwatch.observer — SEC 8-K summary
======================================

Issuer:     Envoy Medical, Inc. (COCH)
CIK:        0001840877
Form:       8-K
Filed at:   2024-06-11T23:59:59+00:00
Accession:  0001213900-24-051511
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Envoy Medical: Dr. Haring-Smith resigns from board; Michael Crowe appointed
---------------------------------------------------------------------------

- Dr. Whitney Haring-Smith resigned effective June 6, 2024; no disagreement.
- Board appointed Michael Crowe on June 7, 2024 to fill vacancy.
- Crowe receives $40k annual cash and 25,000-share option award vesting over 4 years.
- Crowe is SVP Operations at Bioventus, former VP Operations at Abbott Vascular.
- Envoy expects to begin pivotal clinical study for Acclaim CI later in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840877/000121390024051511/0001213900-24-051511-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840877/000121390024051511/ea0207623-8k_envoy.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-051511

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer